Discovery and optimization of antibacterial AccC inhibitors.Cheng, C.C., Shipps, G.W., Yang, Z., Sun, B., Kawahata, N., Soucy, K.A., Soriano, A., Orth, P., Xiao, L., Mann, P., Black, T.
(2009) Bioorg Med Chem Lett 19: 6507-6514
- PubMed: 19875284
- DOI: https://doi.org/10.1016/j.bmcl.2009.10.057
- Primary Citation of Related Structures:
- PubMed Abstract:
The biotin carboxylase (AccC) is part of the multi-component bacterial acetyl coenzyme-A carboxylase (ACCase) and is essential for pathogen survival. We describe herein the affinity optimization of an initial hit to give 2-(2-chlorobenzylamino)-1-(cyclohexylmethyl)-1H-benzo[d]imidazole-5-carboxamide (1), which was identified using our proprietary Automated Ligand Identification System (ALIS).(1) The X-ray co-crystal structure of 1 was solved and revealed several key interactions and opportunities for further optimization in the ATP site of AccC. Structure Based Drug Design (SBDD) and parallel synthetic approaches resulted in a novel series of AccC inhibitors, exemplified by (R)-2-(2-chlorobenzylamino)-1-(2,3-dihydro-1H-inden-1-yl)-1H-imidazo[4,5-b]pyridine-5-carboxamide (40). This compound is a potent and selective inhibitor of bacterial AccC with an IC(50) of 20 nM and a MIC of 0.8 microg/mL against a sensitized strain of Escherichia coli (HS294 E. coli).
Schering-Plough Research Institute, Cambridge, MA 02141, United States. firstname.lastname@example.org